Table 2.
Base Case Results: Cases of clinical infection, hospitalizations, deaths, health-care system costs, and quality-adjusted life years with aQIV and QIV-HD under three relative effectiveness scenarios. All numbers, except for deaths from influenza, are presented rounded to the thousands
| Relative effectiveness (rVE) of aQIV versus QIV-HD | rVE = −2.5% | rVE = 3.2% | rVE = 8.9% |
|---|---|---|---|
| Clinical Influenza Cases (thousands) | |||
| aQIV Strategy | 2,616 | 2,615,577 | 2,615,577 |
| QIV-HD Strategy | 2,606 | 2,628,959 | 2,655,355 |
| Percent Change | -<1% | 1% | 2% |
| Hospitalizations (thousands) | |||
| aQIV Strategy | 22 | 22 | 22 |
| QIV-HD Strategy | 22 | 22 | 23 |
| Percent Change | −0.8% | 1% | 3% |
| Deaths | |||
| aQIV Strategy | 2,800 | 2,800 | 2,800 |
| QIV-HD Strategy | 2,800 | 2,900 | 3,000 |
| Percent Change | −2% | 2% | 6% |
| rVe = −2.5 | rVE = 3.2 | rVE = 8.9 | |
| Average annual discounted health-care system costs for influenza treatment* (thousands) | |||
| aQIV Strategy | € 94,178 | € 94,178 | € 94,178 |
| QIV-HD Strategy | € 93,293 | € 95,388 | € 97,788 |
| Percent Change | −1% | 1% | 4% |
| Average discounted quality-adjusted life years per season of vaccination (thousands) | |||
| aQIV Strategy | 51,414 | 51,414 | 51,414 |
| QIV-HD Strategy | 51,415 | 51,414 | 51,413 |
| Percent Change | <1% | -<1% | -<1% |
* This cost includes influenza treatment costs but not the cost of vaccination.